|
1
|
Solit DB and Rosen N: Hsp90: A novel
target for cancer therapy. Curr Top Med Chem. 6:1205–1214. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maloney A and Workman P: HSP90 as a new
therapeutic target for cancer therapy: The story unfolds. Expert
Opin Biol Ther. 2:3–24. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mahalingam D, Swords R, Carew JS, Nawrocki
ST, Bhalla K and Giles FJ: Targeting HSP90 for cancer therapy. Br J
Cancer. 100:1523–1529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sidera K and Patsavoudi E: HSP90
inhibitors: Current development and potential in cancer therapy.
Recent Pat Anticancer Drug Discov. 9:1–20. 2014.PubMed/NCBI
|
|
5
|
Ferrarini M, Heltai S, Zocchi MR and
Rugarli C: Unusual expression and localization of heat-shock
proteins in human tumor cells. Int J Cancer. 51:613–619. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Neckers L and Neckers K: Heat-shock
protein 90 inhibitors as novel cancer chemotherapeutic agents.
Expert Opin Emerg Drugs. 7:277–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Connell P, Ballinger CA, Jiang J, Wu Y,
Thompson LJ, Höhfeld J and Patterson C: The co-chaperone CHIP
regulates protein triage decisions mediated by heat-shock proteins.
Nat Cell Biol. 3:93–96. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goetz MP, Toft DO, Ames MM and Erlichman
C: The Hsp90 chaperone complex as a novel target for cancer
therapy. Ann Oncol. 14:1169–1176. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schulte TW, Blagosklonny MV, Ingui C and
Neckers L: Disruption of the Raf-1-Hsp90 molecular complex results
in destabilization of Raf-1 and loss of Raf-1-Ras association. J
Biol Chem. 270:24585–24588. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schulte TW, Blagosklonny MV, Romanova L,
Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J and Neckers
LM: Destabilization of Raf-1 by geldanamycin leads to disruption of
the Raf-1-MEK-mitogen-activated protein kinase signalling pathway.
Mol Cell Biol. 16:5839–5845. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neri LM, Borgatti P, Capitani S and
Martelli AM: The nuclear phosphoinositide 3-kinase/AKT pathway: A
new second messenger system. Biochim Biophys Acta. 1584:73–80.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kumar A, Rajendran V, Sethumadhavan R and
Purohit R: AKT kinase pathway: A leading target in cancer research.
ScientificWorldJournal. 2013:7561342013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basso AD, Solit DB, Chiosis G, Giri B,
Tsichlis P and Rosen N: Akt forms an intracellular complex with
heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by
inhibitors of Hsp90 function. J Biol Chem. 277:39858–39866. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma W and Quirion R: The ERK/MAPK pathway,
as a target for the treatment of neuropathic pain. Expert Opin Ther
Targets. 9:699–713. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee JT Jr and McCubrey JA: The Raf/MEK/ERK
signal transduction cascade as a target for chemotherapeutic
intervention in leukemia. Leukemia. 16:486–507. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dou F, Yuan LD and Zhu JJ: Heat shock
protein 90 indirectly regulates ERK activity by affecting Raf
protein metabolism. Acta Biochim Biophys Sin (Shanghai).
37:501–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Johnstone RW, Frew AJ and Smyth MJ: The
TRAIL apoptotic pathway in cancer onset, progression and therapy.
Nat Rev Cancer. 8:782–798. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song JJ and Lee YJ: Differential cleavage
of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation
of the MAPK superfamily. Cell Signal. 20:892–906. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu J, Zhou JY, Wei WZ and Wu GS:
Activation of the Akt survival pathway contributes to TRAIL
resistance in cancer cells. PloS One. 5:e102262010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roder DM: The epidemiology of gastric
cancer. Gastric Cancer. 5(Suppl): 5–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen M, Xu J and Zhao J: Effects of HSP90
inhibitor 17-AAG on cell cycle and apoptosis of human gastric
cancer cell lines SGC-7901. Nan Fang Yi Ke Da Xue Xue Bao.
33:271–275. 2013.(In Chinese). PubMed/NCBI
|
|
23
|
Wainberg ZA, Anghel A, Rogers AM, Desai
AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, et
al: Inhibition of HSP90 with AUY922 induces synergy in
HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol
Cancer Ther. 12:509–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Redlak MJ and Miller TA: Targeting
PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to
deoxycholate-induced apoptosis. Dig Dis Sci. 56:323–329. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hede K: Gastric cancer: Trastuzumab trial
results spur search for other targets. J Natl Cancer Inst.
101:1306–1307. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stebbins CE, Russo AA, Schneider C, Rosen
N, Hartl FU and Pavletich NP: Crystal structure of an
Hsp90-geldanamycin complex: Targeting of a protein chaperone by an
antitumor agent. Cell. 89:239–250. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Supko JG, Hickman RL, Grever MR and
Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as
an antitumor agent. Cancer Chemother Pharmacol. 36:305–315. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma Q, Jiang Q, Pu Q, Zhang X, Yang W, Wang
Y, Ye S, Wu S, Zhong G, Ren J, et al: MicroRNA-143 inhibits
migration and invasion of human non-small-cell lung cancer and its
relative mechanism. Int J Biol Sci. 9:680–692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Köhrmann A, Kammerer U, Kapp M, Dietl J
and Anacker J: Expression of matrix metalloproteinases (MMPs) in
primary human breast cancer and breast cancer cell lines: New
findings and review of the literature. BMC Cancer. 16:1882009.
View Article : Google Scholar
|
|
30
|
da Rocha Dias S, Friedlos F, Light Y,
Springer C, Workman P and Marais R: Activated B-RAF is an Hsp90
client protein that is targeted by the anticancer drug
17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65:10686–10691.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grbovic OM, Basso AD, Sawai A, Ye Q,
Friedlander P, Solit D and Rosen N: V600E B-Raf requires the Hsp90
chaperone for stability and is degraded in response to Hsp90
inhibitors. Proc Natl Acad Sci USA. 103:57–62. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Neckers L and Neckers K: Heat-shock
protein 90 inhibitors as novel cancer chemotherapeutics - an
update. Expert Opin Emerg Drugs. 10:137–149. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang H and Burrows F: Targeting multiple
signal transduction pathways through inhibition of Hsp90. J Mol Med
(Berl). 82:488–499. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koga F, Xu WP, Karpova TS, McNally JG,
Baron R and Neckers L: Hsp90 inhibition transiently activates Src
kinase and promotes Src-dependent Akt and Erk activation. Proc Natl
Acad Sci USA. 103:11318–11322. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Matsuoka T and Yashiro M: The role of
PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel).
6:1441–1463. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hostein I, Robertson D, DiStefano F,
Workman P and Clarke PA: Inhibition of signal transduction by the
Hsp90 inhibitor 17-Allylamino-17- demethoxygeldanamycin results in
cytostasis and apoptosis. Cancer Res. 61:4003–4009. 2001.PubMed/NCBI
|
|
37
|
Powers MV, Clarke PA and Workman P: Dual
targeting of HSC70 and HSP72 inhibits HSP90 function and induces
tumor-specific apoptosis. Cancer Cell. 14:250–262. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim YS, Alarcon SV, Lee S, Lee MJ,
Giaccone G, Neckers L and Trepel JB: Update on Hsp90 inhibitors in
clinical trial. Curr Top Med Chem. 9:1479–1492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jhaveri K, Taldone T, Modi S and Chiosis
G: Advances in the clinical development of heat shock protein 90
(Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755.
2012. View Article : Google Scholar : PubMed/NCBI
|
